Boston Therapeutics to Be Quoted as BTHE on the OTC Bulletin Board

MANCHESTER, NH – Boston Therapeutics, Inc. (OTCBB: BTHE), a developer of diabetes therapeutics, is pleased to announce that it has received clearance by FINRA on February 28, 2012 to be quoted by Glendale Securities, Inc. on the OTC Bulletin Board under the symbol BTHE.

About Boston Therapeutics, Inc.
Boston Therapeutics, headquartered in Manchester, NH, is a leader in the field of glyco-pathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases. The Company’s initial product pipeline is focused on developing and commercializing therapeutic molecules for diabetes: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose excursion, SUGARDOWN®, a non-systemic chewable complex carbohydrate dietary supplement designed to moderate post-meal blood glucose, and IPOXYN™, a systemic, injectable complex carbohydrate-based oxygen therapeutic for limb ischemia. Earlier this year Boston Therapeutics petitioned the U.S. FDA to submit an Abbreviated New Drug Application (ANDA) for chewable Metformin. The Company signed a licensing agreement with Hong Kong-based Advance Pharmaceuticals Co Ltd. and received its first commercial purchase order from a distributor in Italy to market SUGARDOWN®. In 2011 the Company completed a clinical trial with SUGARDOWN®. The Company’s drug candidate PAZ320 is currently in clinical trials at Dartmouth-Hitchcock Medical Center in Hanover, N.H.

Additional information is available at and

About Glendale Securities Inc.

Glendale Securities, Inc. provides securities brokerage services to clients in the United States. It offers online trading services through a Web interface, as well as through a Windows-based downloadable software program. The company is based in Sherman Oaks, California.
Additional information is available at (818) 907-1505

FORWARD-LOOKING STATEMENTS: Any statements in this news release about future expectations, plans and prospects for the Company constitute forward-looking statements as defined in the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements.

More information about those risks and uncertainties is contained and discussed in the Company’s most recent quarterly or annual report and in the Company’s other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company’s views as of the date of this news release and should not be relied upon to represent the Company’s views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company’s views to change, the Company disclaims any obligation to update such forward-looking statements.

SUGARDOWN® and Ipoxyn™ are registered trademarks of Boston Therapeutics, Inc.


Contact Information

Investor Contact:
Ken Tassey
Boston Therapeutics, Inc.
(978) 886-0421


About the StockGuru Leader Board:

We watch for stocks moving up and creating a positive momentum in the market.  We are not compensated for coverage.

Feel free to suggest a stock for coverage if you see it breaking out.  Contact:
IR Affiliates –
StoneBridge Web & SEO –

All content on is original content – with the exception of client news releases. All content is (C) Copyright 2002 to 2012 StockGuru. No content may be used in whole or in part without the express written consent of our Publisher. We encourage web sites interested in our content to offer a reciprocal exchange agreement in exchange for use of some of our content. We do not offer advance approval, but contact our Publisher if you have an interest in repropagating our content. Contact as at: or (469) 252-3030. Mailing address: 1601 Berwick Drive; McKinney, Texas 75070